provenge News
Most Popular provenge Story
What will Dendreon's new chief do about Provenge?
It's safe to say Dendreon ($DNDN) is looking for a new Provenge strategy when board member John Johnson takes over as CEO. The $93,000 prostate-cancer drug, approved to great fanfare in spring 2010, Read more...
Latest Headlines
- February 1, 2012
- January 5, 2012
- November 22, 2011
- November 3, 2011
- October 12, 2011
- October 10, 2011
- September 9, 2011
- September 8, 2011
- September 6, 2011
- August 25, 2011
- August 4, 2011
- July 1, 2011
- June 7, 2011
- May 3, 2011
- March 31, 2011
- March 11, 2011
- March 2, 2011
- January 7, 2011
- November 18, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
